DCLK1-IN-1 |
| Katalog-Nr.GC39486 |
DCLK1-IN-1 ist eine selektive, orale BioverfÜgbarkeit in vivo-kompatible chemische Sonde der Doppelcortin-Ähnlichen Kinase 1 (DCLK1-Kinase)-DomÄne. DCLK1-IN-1 hemmt DCLK1- und DCLK2-Kinasen (IC50: DCLK1 =9,5/57,2 nM und DCLK2 =31/103 nM im Bindungs- bzw. Kinase-Assay). DCLK1-IN-1 zeigt eine geringe ToxizitÄt und kann die DCLK1-Biologie untersuchen und seine Rolle bei Krebs wie DCLK1+ duktales Adenokarzinom des Pankreas (PDAC) bestimmen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2222635-15-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1+ pancreatic ductal adenocarcinoma (PDAC)[1].
[1]. Ferguson FM, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 Apr 6.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *